TH.TO Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: September 17, 2025
Report Source: 2025 2nd Quarter Report
Theratechnologies Inc. Stock Analysis TH.TO
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The company is headquartered in Montreal, Quebec and currently employs 94 full-time employees. The firm offers prescription products for individuals with human immunodeficient virus (HIV) in the United States and its pipeline is focused on specialized therapies designed to address unmet medical needs in both HIV and oncology. The company markets two HIV products, namely EGRIFTA SV and Trogarzo; and has research programs in HIV and oncology. EGRIFTA SV is the therapy for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Trogarzo injection is used with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 who are failing their current regimen. Its pipeline includes Donidalorsen and Olezarsen, and the SORT1+ oncology platform. The firm is also focusing on tesamorelin life-cycle management in lipodystrophy.
Read More Theratechnologies Inc (TH.TO) Chart
Key Statistics of Theratechnologies Inc (TH.TO)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
CAD4.47Volume
35.47KP/E Ratio (TTM)
-52 Week Range
Market Cap
205.53MAvg. Volume
63.63KDividend Yield
-Financial Metrics & Statements of Theratechnologies Inc (TH.TO)
FAQ's for Theratechnologies Inc (TH.TO)
- According to Musaffa’s Shariah screening methodology, Theratechnologies Inc (TH.TO) is currently classified as NOT HALAL as of September 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.